Evolutions in clinical trials: Unlocking new efficiencies in patient recruitment and site collaboration

Challenges and benefits when considering digital components within study protocols

  • Tuesday, July 8, 2025 | 10 am EST (NA) / 3pm GMT (UK) / 4PM CET (EU-Central)
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Speakers

Select a speaker to learn more

Back
Melissa Harris
Head of Global Patient Recruitment and Engagement, Fortrea

Melissa has 23 years of industry experience dedicated to accelerating patient recruitment from all possible feeds including site EHRs, AI and data enabled recruitment channels, digital and online media and community engagement programs. Melissa works to harness the benefits of applying innovative solutions toward successful patient recruitment and retention campaigns while driving health literacy, diversity and inclusion and patient access equity to reduce study burden and facilitate enrollment into everyday life. Melissa heads up Fortrea’s Voice of Patient program to drive patient insights into every step of the drug development paradigm and is a Co-Lead of Fortrea’s Site Advisory Board.

Next speaker
Back
John Kennett, MSc
Director, Global Marketing, Fortrea

JK has over 20 years of experience in the pharmaceutical and CRO industries, with a strong background in strategic delivery. During that time, John has worked in pre-clinical toxicology, clinical pharmacology, first-in-human trials, digital health, site collaboration, patient recruitment, safety and pharmacovigilance, regulatory submission, market access and HEOR strategy, RWE, LTFU and phase IV studies, working across a range of tactics including ghost writing, podcasting, video production, strategy development and product launch.

Next speaker
Back
Cameron Glen, VP
Global Business Development, FurtureMeds

Cameron has a unique blend of industry experience and knowledge. He spent 23 years of his career building & forging alliances and pursuing new business for notable public and private sector players such as Menarini Pharmaceuticals, AstraZeneca, University of Dundee/NHS Tayside, Synexus, and industry-leading CROs such as Covance Inc. (Labcorp R&D) and ICON plc.

Next speaker

Enquiry